Trial Profile
A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Crossover Study of MK-1029 in Adult Subjects With Persistent Asthma Who Remain Uncontrolled While Being Maintained on Montelukast
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs MK 1029 (Primary)
- Indications Asthma
- Focus Adverse reactions; Therapeutic Use
- Acronyms MK-1029-011
- Sponsors Merck Sharp & Dohme
- 28 May 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
- 28 Jan 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 27 Aug 2013 Planned End Date changed from 1 Jan 2014 to 1 May 2014 as reported by ClinicalTrials.gov.